Overview of Dr. Haura
Dr. Eric Haura is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Duke University School of Medicine and has been in practice 23 years. Dr. Haura accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Fax+1 813-745-6817
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
- Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
- Duke University School of MedicineClass of 1994
Certifications & Licensure
- FL State Medical License 2000 - 2025
- NC State Medical License 1999 - 2001
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates Start of enrollment: 2004 Oct 01
- Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Mar 01
- Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation Start of enrollment: 2009 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 156 citationsTGF-β–inducible microRNA-183 silences tumor-associated natural killer cellsSarah S. Donatelli, Junmin Zhou, Danielle L. Gilvary, Erika A. Eksioglu, Xianghong Chen
Proceedings of the National Academy of Sciences of the United States of America. 2014-03-18 - 7 citationsSurgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoa...Valerie W Rusch, Alan Nicholas, G Alexander Patterson, Salama N Waqar, Eric M Toloza
The Journal of Thoracic and Cardiovascular Surgery. 2023-03-01 - 106 citationsNeoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.Jamie E Chaft, Filiz Oezkan, Mark G Kris, Paul A Bunn, Ignacio I Wistuba
Nature Medicine. 2022-10-01
Press Mentions
- Adoptive Cell Therapy plus Checkpoint Inhibitors Show Promise in Non-Small Cell Lung CancerAugust 12th, 2021
- Moffitt Gets $10.2 Million Grant to Develop Lung Cancer TreatmentsJune 29th, 2021
- The Rapid Tissue Donation Program at Moffitt Cancer Center Offers a Feasible Approach to Improve ResearchDecember 13th, 2019
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open AccessCIGNA PPO
Cofinity PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: